Sponsor

Universitaetsmedizin Goettingen

Germany Robert-Koch-Strasse 40, Weende, 37075 Goettingen, Germany

About the sponsor

Research activity includes advanced heart failure, chronic right heart failure, and aortic stenosis with myocardial fibrosis. The portfolio also covers interventions linked to transcatheter aortic valve implantation and cardiac regeneration.

Heart failure and right ventricular dysfunction
Myocardial fibrosis and fibrotic burden
Cardiac imaging and structural heart disease

These studies reflect a strong interest in cardiometabolic and structural cardiac conditions with unmet treatment needs.

About Specializations

Universitaetsmedizin Goettingen runs clinical trials in conditions such as Cardiac failure acute, Cardiac failure chronic, Alport's syndrome, Kearns-Sayre syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

9 clinical trials

Cardiac failure acute

Recruiting

Study on the Safety and Effectiveness of Engineered Human Myocardium for Patients with Terminal Heart Failure

InvestigationalNo placebo

Study on the Safety and Effectiveness of Engineered Human Myocardium for Patients with Terminal Heart Failure

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Allogeneic Induced Pluripotent Stem Cells-Derived Cardiomyocytes And Stromal Cells
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Cardiac failure chronic

Recruiting

Study on Dapagliflozin for Patients with Chronic Right Heart Failure

Registered drug

Study on Dapagliflozin for Patients with Chronic Right Heart Failure

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Alport's syndrome

Recruiting

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug

Germany

Participants:0–17 years · 18–64 years
Substances:Dapagliflozin
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Kearns-Sayre syndrome

Recruiting

Study on the Effects of Calcium Folinate in Patients with Kearns-Sayre Syndrome and Cerebral Folate Deficiency

Registered drugNo placebo

Study on the Effects of Calcium Folinate in Patients with Kearns-Sayre Syndrome and Cerebral Folate Deficiency

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Anhydrous calcium folinate
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Pancreatic carcinoma

Recruiting

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Binge eating

Not recruiting

Study on Hydrocortisone and Food Exposure Therapy for Patients with Binge Eating Disorder

Registered drug

Study on Hydrocortisone and Food Exposure Therapy for Patients with Binge Eating Disorder

Registered drug

Germany

Participants:18–64 years
Substances:Hydrocortisone
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Aortic stenosis

Not recruiting

Study of spironolactone and Dihydralazine for reducing heart muscle scarring in patients with severe aortic valve narrowing after valve replacement procedure

Registered drugNo placebo